Therefore, deciphering novel molecular pathways such as the calp/cast system, sustaining GBM cell stemness, could prospectively serve as a tool for prognostic and/or therapeutic purposes, targeting therapy-resistant GBM stem cells, the population which fuels GBM initiation and recurrence. The gene discussed is KCNIP4; the disease is glioblastoma.